David E. Gerber
Parkland Health & Hospital System · 572 works · 26,022 citations · h-index 60
Top works
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer
- Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
- ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
- Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea
- Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
- Targeted therapies: a new generation of cancer treatments.
- Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non–Small-Cell Lung Cancer
- Impact of Prior Cancer on Eligibility for Lung Cancer Clinical Trials
- Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors
- Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations
- Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition
- Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas1
- Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer